Tryp Therapeutics Submits Investigational New Drug Application to US FDA for Planned Phase 2a Clinical Trial in Patients With IBS at Massachusetts General Hospital
KELOWNA, BC / ACCESSWIRE / May 24, 2023 / Tryp Therapeutics, Inc. (CSE:TRYP)(OTCQB:TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin
Source: finanznachrichten.de